Health

Results: 1837-1848 of 7452

CORE-VNS Study Further Validates Effectiveness of LivaNova’s VNS Therapy on Severe Focal Seizures in Both Children and Adults with Drug-Resistant Epilepsy

PR Newswire associated0

FutureCeuticals, Inc. Announces Peer-Reviewed Publication Highlighting Cellular Health and Immune Support Benefits of vitAlign®

LivaNova Announces CORE-VNS 24-Month Data Show Adjunctive VNS Therapy is Associated with Substantial Reductions in Generalized Tonic-Clonic Seizures in People with Drug-Resistant Epilepsy

Polpharma Group Supports Urgent EU Action to Safeguard Access to Medicines and Strengthen European Pharmaceutical Sovereignty

Sarah Harkcom, General Counsel at Scientist.com, Wins European Legal Innovation & Technology “Innovation Trailblazer” Award

TeleTracking and Palantir Partner to Transform Healthcare Operations with AI-Powered Insights

Figure 1. DAZALS exploratory overall survival analysis at one-year – patients who received 300 mg of dazucorilant compared to patients who received only placebo.

Corcept Presents Results from Phase 2 Study of Dazucorilant in Patients with Amyotrophic Lateral Sclerosis (ALS) at ENCALS 2025 Annual Meeting

Women on “skinny jabs” must use effective contraception, MHRA urges in latest guidance

UPMC Ireland Selects MEDITECH Expanse as the Cornerstone of its Digital Strategy

Sectra's year-end report 2024/2025: Reporting solid growth in a time of change

Fujirebio Announces Strategic Collaboration with Stanford Medicine to Advance Infectious Disease Research

PR Newswire associated0

Telix's Illuccix® PSMA-PET Imaging Agent Approved in Germany